Elanco Animal Health (NYSE:ELAN) Issues Q3 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its third quarter 2026 earnings guidance on Wednesday. The company provided EPS guidance of 0.190-0.220 for the period, compared to the consensus estimate of 0.190. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Elanco Animal Health also updated its FY 2026 guidance to 1.100-1.160 EPS.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. Weiss Ratings raised shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, July 31st. Morgan Stanley upped their target price on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 22nd. Finally, KeyCorp raised their target price on Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Elanco Animal Health presently has an average rating of “Moderate Buy” and an average price target of $29.09.

Elanco Animal Health Stock Down 6.6%

NYSE:ELAN traded down $1.60 during trading hours on Friday, reaching $22.60. The company had a trading volume of 13,454,645 shares, compared to its average volume of 5,531,224. Elanco Animal Health has a twelve month low of $16.15 and a twelve month high of $27.98. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The firm has a market cap of $11.29 billion, a price-to-earnings ratio of -55.23, a P/E/G ratio of 1.73 and a beta of 1.67. The business’s 50-day simple moving average is $24.73 and its two-hundred day simple moving average is $24.10.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.12% and a negative net margin of 3.96%.The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. During the same period last year, the firm posted $0.26 EPS. The business’s revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities analysts expect that Elanco Animal Health will post 1.1 earnings per share for the current year.

Insider Buying and Selling

In other Elanco Animal Health news, insider Rajeev A. Modi acquired 4,911 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the transaction, the insider owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This represents a 3.15% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of the business’s stock in a transaction on Friday, May 15th. The stock was bought at an average cost of $20.09 per share, with a total value of $99,867.39. Following the purchase, the chief executive officer owned 171,971 shares in the company, valued at approximately $3,454,897.39. This represents a 2.98% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Elanco Animal Health

A number of institutional investors have recently modified their holdings of ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Elanco Animal Health during the 1st quarter valued at about $2,065,000. Goldman Sachs Group Inc. lifted its position in Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after acquiring an additional 2,445,872 shares in the last quarter. Empowered Funds LLC boosted its stake in Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after purchasing an additional 4,121 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Elanco Animal Health by 4.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after purchasing an additional 76,408 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in shares of Elanco Animal Health by 2,006.9% in the second quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock worth $4,432,000 after purchasing an additional 295,651 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.